Robert R. Redfield

The first confirmed case of COVID-19 was discovered in the US on January 20, 2020, while Redfield was serving as director of the CDC. Redfield testified to Congress on March 2, 2020, about the outbreak of COVID-19 in the US. Given the lack of testing on patients and healthcare workers requesting testing, Florida Democrat Debbie Wasserman Schultz asked Redfield about who was responsible to ensure testing could be performed on individuals who needed to be tested. Redfield could not name a specific individual and looked to Dr. Anthony Fauci, director of infectious disease at the NIH, who said, "The system is not geared to what we need right now... that is a failing."

On 6 April 2020, Redfield stated on AM 1030 KVOI Radio in Tucson, Arizona, “[t]hose models that were done, they assume only about 50 percent of the American public would pay attention to the recommendations. In fact, what we’re seeing is a large majority of the American public are taking the social distancing recommendations to heart. And I think that’s the direct consequence of why you’re seeing the numbers are going to be much, much, much lower than would have been predicted by the models.".

On 21 May 2020, The Atlantic Magazine reported on the intentional conflation of the viral and antibody testing results that the CDC, under Redfield's leadership, has been compiling data on since the beginning of the year. This conflation of the tests' results has led to misrepresentations in the media and in public opinion of the current state of the virus's spread. Several states have now also adopted this approach for reporting on the number of tests given and their results, and they've used those faulty, unscientific statistics to aid in the planning for reopening their states.

Redfield has served as the director of the CDC since March 26, 2018. In his inaugural address to the CDC Redfield said "[The agency is] science-based and data-driven, and that's why CDC has the credibility around the world that it has.” He was nominated for the post by President Donald Trump, after the President's first appointee resigned in scandal. His nomination was considered controversial, and was opposed by the Center for Science in the Public Interest, which cited Redfield's lack of experience administering a public health agency, his history of scientific misconduct, and his religious advocacy in response to a public health crisis. Mother Jones refers to his advocacy of a religious agenda in response to the AIDS crisis

In 2018, after Redfield was appointed to the CDC, Democrats and watchdog groups criticized his $375,000-a-year salary, which was significantly higher than the $219,700 salary of his predecessor, Tom Frieden, and higher than that of his own boss, Alex Azar, the Secretary of Health and Human Services (and former president of a division of Eli Lilly).

Redfield served as a tenured professor of medicine and microbiology at University of Maryland, Baltimore, chief of infectious disease, vice chair of medicine, and a co-founder and associate director of the Institute of Human Virology at the University of Maryland School of Medicine. Redfield is known for his contributions in this period—in clinical research, in particular, for extensive research into the virology and therapeutic treatments of HIV infection and AIDS. In the early years of investigations into the AIDS pandemic in the 1980s, Redfield led research that demonstrated that the HIV retrovirus could be heterosexually transmitted. He also developed the staging system now in use worldwide for the clinical assessment of HIV infection. Under his clinical leadership at the University of Maryland the patient base grew from just 200 patients to approximately 6,000 in Baltimore and Washington, D.C., and more than 1.3 million in African and Caribbean nations. Under his research leadership his clinical research team successfully competed for and won over 600 million dollars of research funding.

Redfield has received several awards over the course of his career as a physician-scientist, including an honorary degree from the New York Medical College, a lifetime services award from the Institute for Advanced Studies in Immunology and Aging, and the Surgeon General's Physician Recognition Award. In 2012, along with William Blattner, he was named entrepreneur of the year at the University of Maryland. In 2016 he was named the inaugural Robert C. Gallo, MD Endowed Professors in Translational Medicine.

Redfield also served as a member of the President's Advisory Council on HIV/AIDS from 2005 to 2009, and was appointed as chair of the International Subcommittee from 2006 to 2009. He is a past member of the Office of AIDS Research Advisory Council at the National Institutes of Health, the Fogarty International Center Advisory Board at the National Institutes of Health, and the Advisory Anti-Infective Agent Committee of the Food and Drug Administration.

Redfield continued studies of the gp160 vaccine; the results of his 27-author phase II clinical trial were published in the Journal of Infectious Disease in 2000, with Deborah L. Birx as lead author. Redfield's multi-site study was a collaboration between the Department of Defense and the National Institutes of Health, The work did not, however, result in an effective vaccine.

Redfield served on the board of ASAP, which gay groups criticized for anti-gay, conservative Christian policies, such as abstinence-only prevention. Redfield also authored the foreword to the book co-written by ASAP leader W. Shepard Smith, "Christians in the Age of AIDS" which discouraged the distribution of sterile needles to drug users as well as condom use calling them "false prophets." The book described AIDS as "God's judgment" against homosexuals. At the time of his nomination to head the Centers for Disease Control and Prevention, Redfield maintained close ties with anti-gay and anti-HIV activists, although he has publicly supported the use of condoms and denied ever promoting abstinence-only interventions. However, in the 2000s, Redfield was a prominent advocate for the ABCs of AIDS doctrine which promoted abstinence primarily and condoms only a last resort.

In 1996, Redfield retired from the army as a colonel, to concentrate on setting up a multidisciplinary research organization dedicated to developing research and treatment programs for chronic human viral infection and disease. To this end, he co-founded the Institute of Human Virology based at Maryland, together with his HIV research colleague Robert Gallo and viral epidemiologist William Blattner.

In 1993, a U.S. Army investigation determined that Redfield had not committed scientific misconduct, and he was subsequently promoted to colonel. Redfield is quoted in Big Shot: Passion, Politics, and the Struggle for an AIDS Vaccine, the comprehensive book on the controversy, as saying of his accusers, "I am disappointed in the institutions for not holding the individuals accountable for what I consider conduct unbecoming of an officer."

The 1993 investigation did say that Redfield had an "inappropriate" close relationship with the non-governmental group "Americans for a Sound AIDS/HIV Policy" (ASAP), which promoted the gp160 vaccine. The group was founded by evangelical Christians that worked to contain the HIV/AIDS outbreak by advocating for abstinence before marriage, rather than passing out condoms — a view Redfield says he's since changed.

In 1992, the Defense Department investigated Redfield after he was accused of misrepresenting the effects of an experimental HIV vaccine, the study of which he had overseen.

In 1992, the U.S. Senate gave a $20 million appropriation for a private company, MicroGeneSys, to develop a therapeutic HIV vaccine based on the protein gp160, which went into clinical trials. Randy Shilts, author of And The Band Played On, wrote in his followup book that the idea of a therapeutic vaccine was a radical idea that came to Redfield while reading his children a book about Louis Pasteur which he then discussed with Jonas Salk who was in support. At the time a U.S. Army Lieutenant Colonel, Redfield was the army's leading AIDS researcher, and a proponent of the vaccine.

In July 1992, Redfield gave an abstract presentation on the vaccine at the international AIDS conference in Amsterdam. Based on preliminary results of 15 of the 26 patients who got the vaccine, Redfield said that the viral load of patients getting the vaccine was lower than patients who did not get the vaccine. Most researchers believe that viral load is a good indicator of vaccine effectiveness. The vaccine later turned out to be ineffective. Many researchers said that Redfield had made a reasonable interpretation of the preliminary data by selecting only 15 patients who had been on the vaccine for 18 months, but US Air Force scientist Major Craig Hendrix, MD (now at Johns Hopkins) said that Redfield committed scientific misconduct by selecting data that were favorable to the vaccine.

Redfield's medical residency was undertaken at the Walter Reed Army Medical Center (WRAMC) in Washington, D.C., where he completed his postgraduate medical training and internships in internal medicine (1978-1980), as a U.S. Army officer. Redfield completed clinical and research fellowships at WRAMC, in infectious diseases and tropical medicine, by 1982.

Redfield earned a Bachelor of Science from the university's College of Arts and Sciences in 1973. He then attended Georgetown University School of Medicine, and was awarded his Doctor of Medicine in 1977.

Robert Ray Redfield Jr. (born July 10, 1951) is an American virologist. He is the current Director of the Centers for Disease Control and Prevention, and the current Administrator of the Agency for Toxic Substances and Disease Registry, having served in both positions since March 2018.

Born Robert Ray Redfield Jr. on July 10, 1951, Redfield's parents were both scientists at the National Institutes of Health; Redfield's career in medical research was influenced by this background. Redfield attended Georgetown University, and at college worked in Columbia University laboratories where investigations focused on the involvement of retroviruses in human disease.